Akorn, Inc. (AKRX) Acquires Eli Lilly's (LLY) Capastat Sulfate
Akorn, Inc. (NASDAQ: AKRX) has entered into an agreement to acquire from Eli Lilly and Company (NYSE: LLY) all rights in the U.S. and Canada to manufacture, market and sell the lyophilized antibiotic Capastat(R) Sulfate (capreomycin for injection, USP). Akorn will own the Capastat NDA and expects to launch the product in the third quarter of this year.
Raj Rai, Akorn's Interim Chief Executive Officer, stated, "Capastat represents an excellent fit within Akorn's strengths and capabilities. This product has been a mainstay in treating TB for over thirty years and complements Rifampin used in the treatment of tuberculosis, which Akorn currently markets through its joint-venture affiliate, Akorn-Strides."
Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals.[SM]
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.52
-0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
